Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.

Abstract: The present invention relates to a glass article with improved surface quality and to a method of making a glass article.

Abstract: A method for producing a structured glass disk is provided that includes the steps of: providing a glass disk having a thickness of at most 400 ?m; directing and focusing a laser beam onto the glass disk such that the laser beam produces an elongated focus within the glass disk with an intensity sufficient to produce damage within the glass disk along the elongated focus; moving the laser beam and the glass disk relative to one another to insert damage zones along a ring-shaped path so that a workpiece is defined in the glass disk with the ring-shaped path encompassing the workpiece and with the workpiece remaining connected to the glass disc; exposing the glass disk to an etchant so that the etchant intrudes into the damage zones; and chemically toughening the glass disk with the workpiece.

Abstract: The present invention relates to a ligand-drug conjugate of an exatecan analogue, a preparation method therefor and an application thereof. Specifically, the present invention provides a ligand-drug conjugate having a structure shown in formula (-D), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in preparation of drugs for treating cancers by means of receptor regulation. The definition of each substituent in formula (-D) is the same as that in the description.

Abstract: The present disclosure relates to fused imidazole derivatives, preparation methods and medical use thereof. Specifically, the present disclosure relates to a fused imidazole derivative represented by the general formula (I), the preparation method thereof, and the pharmaceutical composition containing the same, as well as the use as a therapeutic agent, especially as GLP-1 receptor agonists, and the use thereof in the preparation of medicaments for the treatment and/or prevention of diabetes. The substituents of general formula (I) are the same as defined in the specification.

Abstract: Provided is an anti-G protein-coupled receptor family class C group 5 member D (GPRC5D) antibody or a fragment thereof. Also provided is the use of the antibody or fragment thereof as an active ingredient for treatment of tumors or cancers. In addition, further provided is a bispecific antibody comprising the antibody or fragment thereof and aiming at GPRC5D and CD3.

Abstract: The present disclosure relates to a heterocyclic compound, a method for preparing same, and pharmaceutical use thereof. Specifically, the present disclosure relates to a heterocyclic compound represented by general formula (I), a method for preparing same, a pharmaceutical composition comprising same, and use thereof as a therapeutic agent, particularly, use thereof as an Nav inhibitor and use thereof in preparing a medicament for treating and/or alleviating pain and a pain-related disease. Groups in general formula (I) are as defined in the description.

Abstract: Disclosed is a pyrazolo-heteroaryl derivative, a preparation method therefor, and medical use thereof. In particular, the present invention relates to a pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, particularly as ATR kinase inhibitor and in the preparation of drugs for the treatment and/or prevention of hyperproliferative diseases. The definition of each group in the general formula (I) is identical as in the specification.

Abstract: Provided is an antibody molecule or antigen-binding fragment thereof capable of binding to the human PD-L1. Also provided is the use of the antibody molecule or antigen-binding fragment thereof in the preparation of a medicament for treating tumors or cancers. Compared with the existing anti-PD-L1 antibodies, the provided antibody has superior affinity and dissociation rate for PD-L1, lower immunogenicity, and better tumor inhibition effects.

Abstract: Provided are a pharmaceutically acceptable salt and a crystal form of a nitrogen-containing bridge heterocyclic derivative, and a method for preparing same. Specifically provided are different salt forms and crystal forms of salts of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octyl-1-yl)benzoic acid, and a method for preparing same. The provided crystal forms of salts of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octyl-1-yl)benzoic acid have good stability and can be better used for clinical treatment.

Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Abstract: A storage and charging integrated device is provided, which includes an upper shell and a lower shell that are interlocked, a first PCB conductive board, a locking piece, a toggle piece, and a winding reel. The locking piece and the toggle piece are both provided inside the upper shell and can rotate relative to the upper shell. The toggle piece can toggle the locking piece to rotate, and after rotating at a fixed angle, the locking piece is clamped to the toggle piece. During a rotation process of the winding reel, the toggle piece can be toggled to rotate. This storage and charging integrated device added an additional clamp disk to the basic structure of the existing storage and charging device. The clamp disks can be linked to each other, and the clamp disk can also be linked to a charging cable winding reel.

Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Abstract: The present disclosure relates to a pharmaceutically acceptable salt and a crystal form of a fused pyridine ring derivative and a preparation method therefor. Specifically, the present disclosure relates to a choline salt, sodium salt, potassium salt, calcium salt, arginine salt, lysine salt, meglumine salt, ethanolamine salt, hydrosulfate, hydrochloride, tartrate, maleate, citrate, malate, p-toluenesulfonate, and mesylate, and a crystalline form of a compound as represented by formula (I).

Abstract: An ultrathin chemically toughened and subsequently etched glass article is provided. The article has a thickness of less than or equal to 0.4 mm and a breakage height (given in mm) of more than 200 multiplied by the thickness (t given in mm)). Further, the article has a breakage bending radius (given in mm) of less than 100000 multiplied by the thickness (t given in mm) and divided by a surface compressive stress (in MPa) measured at a first surface.

Abstract: The present application relates to an anti-CD47 single-domain antibody and a use thereof, and a method for preparing the antibody. The single-domain antibody comprises a CDR selected from the following CDRs: (1) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO:3; or (2) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.

Abstract: The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutical composition comprising said derivative, a use thereof as an estrogen receptor modulator, and a use thereof in preparing a drug for treating estrogen receptor-mediated or dependent diseases or disorders. The substituents in general formula (I) are the same as those defined in the description.

Abstract: A fused pyridine ring derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, particularly, in preparation of drugs for preventing and/or treating HIV infection.

Abstract: The present invention relates to a flexible glass element and to a stack assembly comprising the glass element. The invention also relates to a method of producing the glass element or stack assembly comprising the same.

Abstract: The present disclosure relates to bendable elements. The bendable elements can be used in display covers for electronic devices such as smart phones. The elements have reduced delayed elastic deformation or creep when released from the influence of persistent mechanical stresses, e.g. unfolded from a folded position. The present disclosure also relates to covers for color filters, filter printed electronics, sensors for touch control panels, fingerprint sensors, mobile electronic devices, bendable/foldable displays that include the bendable elements as substrates, or other applications where a combination of high chemical stability, temperature stability, low gas permeability, flexibility, high strength, low thickness and premium cosmetic appearance is necessary. Besides consumer and industrial electronics the present disclosure could also be used for protection applications in industrial production or metrology.